Product Description
Carboplatin interferes with the development of the genetic material in a cell, the DNA. This stops it from dividing into 2 new cells and kills it. Carboplatin is a chemotherapy treatment for many different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/carboplatin)
Mechanisms of Action: DNA Synthesis Inhibitor,Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Kazakhstan, Kenya, Korea, Latvia, Malaysia, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 272
Highest Development Phases
Phase 3: Bladder Cancer|Breast Cancer|Carcinosarcoma|Cervical Cancer|Chemotherapy-induced Peripheral Neuropathy|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Endometrioid Carcinoma|Fallopian Tube Cancer|Fallopian Tube Diseases|Glioblastoma|Head and Neck Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Mesothelioma|Mixed Tumor, Mullerian|Nasopharyngeal Cancer|Neuroblastoma|Non-Small-Cell Lung Cancer|Nose Cancer|Other|Ovarian Cancer|Ovarian Diseases|Pain Unspecified|Peripheral Nervous System Diseases|Peritoneal Cancer|Primary Central Nervous System Lymphoma|Prostate Cancer|Retinoblastoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Uterine Cancer
Phase 2: Adenocarcinoma|Adenoid Cystic Carcinoma|Anus Cancer|Brain Cancer|Carcinoma, Adenosquamous|Carcinoma, Merkel Cell|Esophageal Cancer|Gliosarcoma|Laryngeal Cancer|Lip Cancer|Lung Cancer|Male Breast Cancer|Mouth Cancer|Neoplastic Cells, Circulating|Neuroendocrine Carcinoma|Oncology Unspecified|Oropharyngeal Cancer|Pancreatic Cancer|Papillary Adenocarcinoma|Papillary Carcinoma|Penile Cancer|Penile Diseases|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Small Cell Carcinoma|Thymoma|Urogenital Cancer|Urologic Cancer
Phase 1: Epilepsy|Gastrointestinal Cancer|Kidney Cancer|Kidney Diseases|Melanoma|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
|
| HR-NBL2 | P3 |
Active, not recruiting |
Neuroblastoma |
2031-09-24 |
|
| Glo-BNHL | P3 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2031-05-01 |
|
| RELATIVITY1093 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-07-30 |